1. EXPORTING FINISHED PRODUCTS

Global business division of Biopharmartis is constantly moving into overseas expansion through world-wide permission for registration of various finished products manufactured by Hyundai Pharm.

Moolpas-F solution and Bumooly-S solution, two leading brands in Hyundai Pharm, have successfully approved from US FDA on May of 2014, and are expected to launch in US market from this June. Moolpas-F solution already has been exported to Hong Kong and Southeast Asian market consistently, and the US FDA approval will benefit these two markets grow larger mainly based on Southeast Asian market.

Minoxyl (Minoxidil) solution, which occupies over 85% of the domestic market share, has been successfully sold in Vietnam and Hong Kong after registration. Varosc (Amlodipine)tablet is a product for hypertension and has been exported to Hong Kong and Vietnam. Varosc tablet has also been approved in Cambodia, and it will be launched in near future. Olapin (Olanzapine) tablet for schizophrenia, and Mirtapin (Mirtanzapine) tablet for Alzheimer¡¯s disease have been approved in Hong Kong in 2014.

2. TECHNOLOGY TRANSFER (OUT LICENSING)

A number of countries already saw the value of specialized technologies of Biopharmartis based on own core-technologies. Especially, the products, which bypassed the original patents, are receiving attention in the world after successful technology transfer contracts with Europe and Central & South America.

Tamirin(Galantamine) SR tablet, which bypassed the original formulation patent as well, is currently in process of registration in 20 countries including Central &South America. Also, Biopharmartis recently signed on the technology transfer agreement as to Pramipexole SR tablet with a German company for whole European market as well as the other countries. Furthermore, Ibandronate, Telmisartan combination and the other products based on our own core technology are in process of negotiating about out-licensing.

Biopharmartis will keep developing plenty of products that the market wants, and be always ready to discuss about business collaboration with any company in the world.


3. CROSS /IN LICENSING

In today¡¯s intensely competitive environment, Biopharmartis is augmenting our product pipelines by both developing drugs on our own and in-licensing proprietary compounds or drug discovery-related technologies from smaller biotechnology companies. We have evaluated partnership opportunities and determined the optimal timing and investment policy, for proposed alliances in the face of technological and market uncertainties and budgetary restrictions.

In terms of intellectual property, we has been expanded the scope and level of patent rights and acquired the complementary proprietary asset under our strategic patent policy assuring the negotiation power during the licensing process.

Our strengths on IP management and global extension make us diversify our collaboration strategy, so our licensing policy has not only one-time transaction such as license in and out but also cross-licensing as a mean of strategic alliances, both reducing accidental infringements cost and erecting barriers for new entrants.


4. DIRECT MARKET ENTRY

Biopharmartis also enters into the overseas market directly.

For example, Surfolase (Acebrophylline) capsule was an in-licensed product from the original company in 1998 and Biopharmartis is manufacturing with API supplied by original company around for 15 years. Biopharmartis has recently got the marketing authorization for China and East Asia. As the compound was not launched in China, Biopharmartis should conduct the clinical trial. According to the schedule, Biopharmartis estimate that it is going to be launched late of 2017 in China. Therefore, we are highly expecting superior improvement in the market of China with this opportunity.

Also, BPS-015 (as IMDs) of Biopharmartis is supposed to enter into the market of US and Europe in 2015.